Cellectis SA (CLLS)

Currency in USD
4.420
+0.150(+3.51%)
Closed·
4.510+0.090(+2.04%)
·

CLLS Earnings

Latest Release
Mar 19, 2026
EPS / Forecast
-0.26 / -0.29
Revenue / Forecast
12.2M / 10.02M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/03--/-0.260--/13.02M----Free Sign Up
2025/12-0.260/-0.29512.20M/10.02M+11.8%+21.76%Free Sign Up
2025/090.010/-0.23437.16M/8.52M+104.28%+336.15%Free Sign Up
2025/06-0.240/-0.20018.19M/11.03M-20%+64.91%Free Sign Up
2025/03-0.170/-0.24012.00M/11.96M+29.17%+0.33%Free Sign Up
2024/12-0.160/-0.09033.22M/21.71M-77.78%+53.02%Free Sign Up
2024/09-0.230/-0.20018.05M/9.77M-15%+84.75%Free Sign Up
2024/06-0.280/-0.2909.50M/3.47M+3.45%+173.78%Free Sign Up
2024/030.080/0.0806.50M/6.50M0%0%Free Sign Up
2023/12-0.640/-0.6401.99M/1.99M0%0%Free Sign Up

All numbers in USD

Cellectis SA Earnings Call Summary for Q4/2025

  • Cellectis Q4 2025 EPS of -$0.19 beat forecast of -$0.2948 by 35.55%; revenue of $17.1M exceeded $10.02M estimate by 70.66%, driving 2% stock gain.
  • Cash position stands at $211M as of Dec 31, 2025, with runway extending through H2 2027; FY2026 quarterly EPS guidance set at -$0.02.
  • Internal manufacturing capabilities validated with 68% overall response rate, significantly outperforming external production in lasme-cel and eti-cel programs.
  • Key data readouts for lasme-cel and eti-cel programs expected in 2026; company expanding Paris and Raleigh facilities to support growth.
  • Stock rose to $3.55 in premarket trading, within 52-week range of $1.10-$5.48; faces risks from regulatory hurdles and CAR-T market competition.
Last Updated: 2026-03-20, 09:00 a/m
Read Full Transcript

FAQ

What Is Cellectis's Earnings Per Share (TTM)?

The Cellectis EPS (TTM) is -0.674.

When Is The Next Cellectis Earnings Date?

Cellectis will release its next earnings report on Apr 30, 2026.

What Is Cellectis’s Revenue Forecasts For Upcoming Quarters?

Cellectis’s revenue forecast is 13.02M.

How Did Cellectis React to the Company's Latest Earnings Report?

Cellectis reported a +11.8% EPS surprise and a +21.76% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -3.750%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.